|1.||Hruby, Dennis E: 24 articles (07/2015 - 01/2007)|
|2.||Jordan, Robert: 21 articles (03/2013 - 10/2005)|
|3.||Jones, Kevin F: 8 articles (01/2013 - 02/2008)|
|4.||Grosenbach, Douglas W: 6 articles (07/2015 - 02/2008)|
|5.||Chinsangaram, Jarasvech: 6 articles (03/2013 - 05/2009)|
|6.||Tyavanagimatt, Shanthakumar R: 6 articles (03/2013 - 05/2008)|
|7.||Bolken, Tove' C: 6 articles (09/2012 - 05/2008)|
|8.||Honeychurch, Kady M: 4 articles (07/2015 - 07/2012)|
|9.||Berhanu, Aklile: 4 articles (07/2015 - 02/2008)|
|10.||Andrei, Graciela: 4 articles (05/2015 - 01/2007)|
12/01/2013 - "Tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox-infected humans. "
01/12/2010 - "These findings suggest that ST-246 may be effective in controlling smallpox or other pathogenic orthopoxviruses in some immunodeficient human populations for whom the vaccine is contraindicated."
12/01/2013 - "In this study, the efficacy of tecovirimat was evaluated in both a prelesional and postlesional setting in nonhuman primates challenged intravenously with 1 × 10(8) PFU of Variola virus (VARV; the causative agent of smallpox), a model for smallpox disease in humans. "
12/01/2013 - "Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)."
03/01/2013 - "The orally available antiorthopoxvirus drug tecovirimat has recently completed Phase 2 clinical trials and shows promise as a smallpox control agent. "
01/01/2013 - "Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection."
04/01/2007 - "Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection."
02/01/2007 - "Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice."
07/01/2015 - "In these scenarios, tecovirimat treatment is required to control the outbreak (total number of cases under an order of magnitude more than the number of initial infections). "
12/01/2013 - "Although clinical disease was evident in tecovirimat-treated animals, it was generally very mild and appeared to resolve earlier than in placebo-treated controls that survived infection. "
01/12/2010 - "After lethal challenge with the Western Reserve strain of vaccinia, Nude, SCID, and J(H) knockout mice additionally depleted of CD4(+) and CD8(+) T cells were not fully protected by ST-246, although survival was significantly extended. "
12/01/2009 - "Treatment with ST-246, a small-molecule inhibitor of virus egress, has been shown to provide protection against severe disease and death induced by several members of the poxvirus family, including vaccinia, variola, and monkeypox viruses. "
01/01/2008 - "Our observations support that vaccinia, cowpox and camelpox viruses exhibit different levels of sensitivity to ST-246 because of dissimilarities between their ways of propagation, and provide a better understanding of the mode of action of ST-246."
01/01/2007 - "Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures."
11/01/2012 - "We describe a patient with PV who required treatment with vaccinia immune globulin and who received 2 investigational agents, ST-246 and CMX001. "
05/01/2009 - "ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification."
04/01/2007 - "Efficacy of the new antipoxvirus compound ST-246 was evaluated as treatment of monkeypox (MPX) virus infection in a ground squirrel model of the disease. "
10/01/2005 - "ST-246 is a low-molecular-weight compound (molecular weight = 376), that is potent (concentration that inhibited virus replication by 50% = 0.010 microM), selective (concentration of compound that inhibited cell viability by 50% = >40 microM), and active against multiple orthopoxviruses, including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), and variola viruses. "
|5.||Body Weight (Weight, Body)
02/01/2007 - "ST-246 administered once daily by oral gavage to mice infected intranasally with CV beginning 4 h or delayed until 72 h postinoculation was highly effective when given for a 14-day duration using 100, 30, or 10 mg/kg of body weight. "
05/01/2009 - "ST-246 administered at 3 days postinfection (which corresponds to the secondary viremia stage of disease) at four different doses (from 100 mg/kg of body weight down to 3 mg/kg) once a day for 14 days was able to offer NHP 100% protection from a lethal infection with monkeypox virus and reduce the viral load and lesion formation. "
11/01/2007 - "ST-246 was given at 10, 3, or 1 mg/kg of body weight with or without CMX001 at 3, 1, or 0.3 mg/kg to evaluate potential synergistic interactions. "
|1.||Secretory Immunoglobulin A (SIgA)
|3.||Antiviral Agents (Antivirals)
|4.||cidofovir hexadecyloxypropyl ester
|10.||Ethyl Ether (Ether)